High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging

Journal of Immunological Methods

Volumn 387, Issue 1-2, 2013, Pages 11-20

  Ortega, Céline ^a   Herbet, Amaury ^a   Richard, Sophie ^a   Kersual, Nathalie ^c   Costa, Narciso ^a   Pèlegrin, André ^c   Ducancel, Frédéric ^a   Couraud, Jean Yves ^b   Navarro Teulon, Isabelle ^c   Boquet, Didier ^a  

^a CEA SACLAY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Antibody; Cytoplasmic prokaryotic expression; Diabody; Human anti M llerian hormone receptor; Ovarian cancer; Refolding

Indexed keywords

MONOCLONAL ANTIBODY; MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR DIABODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; OVARY CANCER; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INCLUSION BODIES; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PROTEIN BINDING; PROTEIN REFOLDING; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS;

PROKARYOTA;

EID: 84871436114     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.08.003     Document Type: Article

References (35)

1. Abès R., Teillaud J.-L. Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev. 2011, 30:111.
2. Andersen D.C., Reilly D.E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 2004, 15:456.
3. Asano R., Kudo T., Makabe K., Tsumoto K., Kumagai I. Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett. 2002, 528:70.
4. Asano R., Nakayama M., Kawaguchi H., Kubota T., Nakanishi T., Umetsu M., Hayashi H., Katayose Y., Unno M., Kudo T., Kumagai I., Asano R., Nakayama M., Kawaguchi H., Kubota T., Nakanishi T., Umetsu M., Hayashi H., Katayose Y., Unno M., Kudo T., Kumagai I. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system, Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system. FEBS J. 2012, 279:223.
5. Bakkum-Gamez J.N., Aletti G., Lewis K.A., Keeney G.L., Thomas B.M., Navarro-Teulon I., Cliby W.A. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol. Oncol. 2008, 108:141.
6. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10:345.
7. Berkmen M. Production of disulfide-bonded proteins in Escherichia coli. Protein Expr. Purif. 2012, 82:240.
8. Bes C., Troadec S., Chentouf M., Breton H., Dominique Lajoix A., Heitz F., Gross R., Pluckthun A., Chardes T. PIN-bodies: a new class of antibody-like proteins with CD4 specificity derived from the protein inhibitor of neuronal nitric oxide synthase. Biochem. Biophys. Res. Commun. 2006, 343:334.
9. Boquet D., Créminon C., Clément G., Frobert Y., Nevers M.-C., Essono S., Grassi J. Quantitative measurement of bitagged recombinant proteins using an immunometric assay: application to an anti-substance P recombinant antibody. Anal. Biochem. 2000, 284:221.
10. Cai W., Olafsen T., Zhang X., Cao Q., Gambhir S.S., Williams L.E., Wu A.M., Chen X. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 2007, 48:304.
11. Chen L.H., Huang Q., Wan L., Zeng L.Y., Li S.F., Li Y.P., Lu X.F., Cheng J.Q. Expression, purification, and in vitro refolding of a humanized single-chain Fv antibody against human CTLA4 (CD152). Protein Expr. Purif. 2006, 46:495.
12. Clement G., Boquet D., Mondoulet L., Lamourette P., Bernard H., Wal J.M. Expression in Escherichia coli and disulfide bridge mapping of PSC33, an allergenic 2S albumin from peanut. Protein Expr. Purif. 2005, 44:110.
13. di Tommaso A., Juste M.O., Martin-Eauclaire M.-F., Dimier-Poisson I., Billiald P., Aubrey N. Diabody mixture providing full protection against experimental scorpion envenoming with crude Androctonus australis venom. J. Biol. Chem. 2012, 287:14149.
14. Di Tommaso A., Juste M.O., Martin-Eauclaire M.-F., Dimier-Poisson I., Billiald P., Aubrey N. A diabody cocktail providing full protection against experimental scorpion envenoming with crude Androctonus australis venom. J. Biol. Chem. 2012.
15. Essono S., Clément G., Padiolleau-Lefevre S., Créminon C., Grassi J., Boquet D. Peptide mass-assisted antibody cloning strategy for accurate characterization of potential therapeutic monoclonal antibodies against neurodegenerative diseases. Protein Eng. Des. Sel. 2010, 23:203.
16. Féraudet C., Morel N., Simon S., Volland H., Frobert Y., Créminon C., Vilette D., Lehmann S., Grassi J. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J. Biol. Chem. 2005, 280:11247.
17. Hayashi H., Asano R., Tsumoto K., Katayose Y., Suzuki M., Unno M., Kodama H., Takemura S.ichi, Yoshida H., Makabe K., Imai K., Matsuno S., Kumagai I., Kudo T. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol. Immunother. 2004, 53:497.
18. Holliger P., Manzke O., Span M., Hawkins R., Fleischmann B., Qinghua L., Wolf J., Diehl V., Cochet O., Winter G., Bohlen H. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res. 1999, 59:2909.
19. Horton R.M., Hunt H.D., Ho S.N., Pullen J.K., Pease L.R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 1989, 77:61.
20. Hudson P.J., Kortt A.A. High avidity scFv multimers; diabodies and triabodies. J. Immunol. Methods 1999, 231:177.
21. Humphreys D.P., Glover D.J. Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr. Opin. Drug Discov. Dev. 2001, 4:172.
22. Kaur S., Venktaraman G., Jain M., Senapati S., Garg P.K., Batra S.K. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012, 315:97.
23. Krebber A., Bornhauser S., Burmester J., Honegger A., Willuda J., Bosshard H.R., Pluckthun A. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods 1997, 201:35.
24. Miller J., Doss M., McQuillen R., Shaller C., Tolner B., Yu J., Chester K., Robinson M. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biol. 2012, 33:617.
25. Olafsen T., Wu A.M. Antibody vectors for imaging. Semin. Nucl. Med. 2010, 40:167.
26. Olafsen T., Sirk S.J., Olma S., Shen C.K.-F., Wu A.M. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumor Biol. 2012, 33:669.
27. Padiolleau-Lefevre S., Alexandrenne C., Dkhissi F., Clement G., Essono S., Blache C., Couraud J.-Y., Wijkhuisen A., Boquet D. Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: Implications for therapeutic use in prion diseases. Mol. Immunol. 2007, 44:1888.
28. Pepinsky R.B. Selective precipitation of proteins from guanidine hydrochloride-containing solutions with ethanol. Anal. Biochem. 1991, 195:177.
29. Salhi I., Cambon-Roques S., Lamarre I., Laune D., Molina F., Pugnière M., Pourquier D., Gutowski M., Picard J.-Y., Xavier F., Pèlegrin A., Navarro-Teulon I. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem. J. 2004, 379:785.
30. Takemura S.ichi, Asano R., Tsumoto K., Ebara S., Sakurai N., Katayose Y., Kodama H., Yoshida H., Suzuki M., Imai K., Matsuno S., Kudo T., Kumagai I. Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng. Des. Sel. 2000, 13:583.
31. Tsumoto K., Shinoki K., Kondo H., Uchikawa M., Juji T., Kumagai I. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent-application to a human single-chain Fv fragment. J. Immunol. Methods 1998, 219:119.
32. Tsumoto K., Arakawa T., Chen L. Step-wise refolding of recombinant proteins. Curr. Pharm. Biotechnol. 2010, 11:285.
33. Umetsu M., Tsumoto K., Hara M., Ashish K., Goda S., Adschiri T., Kumagai I. How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J. Biol. Chem. 2003, 278:8979.
34. Wu A.M. Antibodies and antimatter: the resurgence of immuno-PET. J. Nucl. Med. 2009, 50:2.
35. Zhang M., Zhang Z., Garmestani K., Goldman C.K., Ravetch J.V., Brechbiel M.W., Carrasquillo J.A., Waldmann T.A. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res. 2004, 64:5825.